UK-wide rectal cancer study helps improve radiotherapy standards across the country

A UK-wide cancer study, ARISTOTLE, has helped establish new standards for planning and delivering radiotherapy for patients with locally advanced rectal cancer, benefiting patients across the UK, including those in northeast Scotland. The study, published in Lancet Oncology, investigated the addition of the chemotherapy drug irinotecan to the current standard treatment of radiotherapy and capecitabine.

However, the results showed that adding irinotecan did not improve patients' chances of remaining free from cancer after treatment and was associated with more side effects. Despite this, the trial has delivered important and lasting benefits for cancer care across the UK by developing a new, consistent approach to planning and delivering pelvic radiotherapy, introducing a comprehensive quality assurance program, and running educational workshops to share best practices and improve standards of care.

Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.